ORBIS project focused on biopharmaceutics, preformulation, dosage forms, and pharmaceutical technology through international research internships.
UNIVERSITY OF CENTRAL FLORIDA
Major US research university contributing to European MSCA programmes across pharmaceutical sciences, coastal risk modelling, and social inclusion.
Their core work
The University of Central Florida is a large US public research university based in Orlando, Florida, participating in European research through Marie Skłodowska-Curie staff exchange and fellowship programmes. Their H2020 involvement spans pharmaceutical sciences (drug delivery, biopharmaceutics), quantum physics, social sciences around mega sports events, and coastal hazard modelling. UCF contributes as a third-party partner, providing US-based research capacity and transatlantic knowledge exchange rather than leading EU consortia directly.
What they specialise in
NHQWAVE project on non-Hermitian quantum wave engineering (2016-2020).
SpaDeRisks project (2022-2025) on spatial dependencies of storm surges and global flood risk assessment.
EventRights project addressing inequality, diversity, and human rights in hosting mega sports events.
How they've shifted over time
UCF's early H2020 engagement (2016-2018) centred on hard sciences — quantum physics and pharmaceutical technology including drug delivery, biopharmaceutics, and medicinal chemistry. Their more recent projects (2018-2024) shifted markedly toward applied social science and environmental risk, covering mega sports event governance, human rights, and coastal flooding models. This diversification suggests UCF's European engagement draws from multiple faculties rather than a single research group.
UCF's H2020 portfolio is broadening from hard sciences toward environmental and social science topics, suggesting growing interest in interdisciplinary transatlantic collaboration.
How they like to work
UCF participates exclusively as a third-party partner — never as coordinator or even a direct consortium member. This is typical for non-EU institutions joining MSCA exchange programmes to provide complementary expertise and host visiting researchers. Despite only four projects, they have connected with 36 unique partners across 17 countries, indicating they serve as a valued transatlantic node rather than a deep repeat collaborator with specific European groups.
UCF has collaborated with 36 unique partners spanning 17 countries through just 4 MSCA projects, reflecting the large consortium sizes typical of MSCA-RISE actions. Their network is geographically broad, connecting European institutions with US-based research capacity.
What sets them apart
As a major US research university, UCF offers European consortia a transatlantic bridge — access to American research infrastructure, student talent, and a non-EU perspective that MSCA programmes specifically encourage. Their topical breadth across pharma, physics, social science, and environmental modelling means they can contribute to diverse consortium needs. For European coordinators, UCF is a proven third-country partner familiar with H2020 programme requirements.
Highlights from their portfolio
- ORBISComprehensive biopharmaceutical internship programme covering the full drug development pipeline from medicinal chemistry to dissolution and biomedical analysis.
- SpaDeRisksMost recent project (2022-2025) tackling global storm surge risk — positions UCF in the growing climate adaptation research space.